ArticleAnnals of nuclear medicine2025
Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn peptide receptor radionuclide therapy (PRRT) using lutetium-177-labeled DOTA-Tyr3-octreotate ([
methodsThis study analyzed 111 PRRT cycles administered to 36 patients between September 2021 and August 2024. Late EDR-1 m was set as the dependent variable, whereas total radiopharmaceutical uptake (LUTtotal), dose per body weight, creatinine clearance (CCr), and albumin-bilirubin (ALBI) score were set as the independent variables in the multiple regression analysis. LUTtotal was calculated using SPECT/CT data acquired after the patient left the radiation therapy room, defining the volume of interest (VOI) as the area with SUVmean + 2SD or higher in the skeletal muscle. The VOI volume multiplied by the SUVmean was used to define LUTtotal. In addition, using [
resultsThe median measured Late EDR-1 m was 8.0 (range, 4.0-26.0) μSv/h. LUTtotal and dose per body weight were significantly correlated with Late EDR-1 m, whereas CCr and ALBI scores were not. Based on the results of the multivariate analysis, the predictive equation using the dose per body weight, assuming a dosage of 7400 MBq and OCTtotal, achieved a root mean square error (RMSE) of 2.24 μSv/h. In subsequent test cases, the RMSE was 3.47 μSv/h.
conclusionsLate EDR-1 m is significantly correlated with LUTtotal and dose per body weight. It can be accurately predicted using [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.